Spyre Therapeutics (SYRE) director-affiliated funds receive 8,026-share option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. reported a routine insider equity award involving director Tomas Kiselak and Fairmount-affiliated funds. An option was granted covering 8,026 shares of common stock at an exercise price of $72.51 per share, expiring on May 27, 2036. The option vests in full on the earlier of May 27, 2027 or the company’s 2027 annual stockholder meeting, subject to Mr. Kiselak’s continued service. Under his arrangement with Fairmount Funds Management LLC, any net cash or stock from this option is for the benefit of Fairmount-managed investment vehicles, and Mr. Kiselak disclaims beneficial ownership except for his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Fairmount Funds Management LLC, Kiselak Tomas, Fairmount Healthcare Fund II L.P.
Role
null | null | null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 8,026 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 8,026 shares (Indirect, By Tomas Kiselak)
Footnotes (1)
- This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to Tomas Kiselak's continuous service to the Issuer through the applicable vesting date. Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.
Key Figures
Option grant size: 8,026 shares
Exercise price: $72.51 per share
Options after grant: 8,026 options
+2 more
5 metrics
Option grant size
8,026 shares
Stock Option (Right to Buy) underlying common shares
Exercise price
$72.51 per share
Conversion or exercise price of granted options
Options after grant
8,026 options
Total derivative securities following transaction
Expiration date
May 27, 2036
Option expiration for this grant
Vesting date trigger
May 27, 2027
Earlier of this date or 2027 annual meeting, subject to service
Key Terms
Stock Option (Right to Buy), beneficial ownership, pecuniary interest, derivative, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
beneficial ownership financial
"Mr. Kiselak therefore disclaims beneficial ownership of the option"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein"
derivative financial
"transaction_type: derivative"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
continuous service financial
"subject to Tomas Kiselak's continuous service to the Issuer"
FAQ
What did the Spyre Therapeutics (SYRE) Form 4 disclose about insider equity awards?
The Form 4 shows a grant of stock options covering 8,026 shares of Spyre Therapeutics common stock. These options were awarded in connection with director Tomas Kiselak’s service and are linked to investment vehicles managed by Fairmount Funds Management LLC.
What is the exercise price and term of the Spyre Therapeutics (SYRE) options granted?
The options have an exercise price of $72.51 per share and expire on May 27, 2036. This gives the holder a long-dated right to buy Spyre common stock at that fixed price if the options vest and are exercised.
When do the newly granted Spyre Therapeutics (SYRE) options vest?
The options vest and become fully exercisable on the earlier of May 27, 2027 or the 2027 annual meeting of stockholders. Vesting is conditioned on Tomas Kiselak’s continuous service to Spyre Therapeutics through the applicable vesting date.
Who effectively benefits from the Spyre Therapeutics (SYRE) option grant reported for Tomas Kiselak?
Under Kiselak’s arrangement with Fairmount Funds Management LLC, any net cash or stock from the option is for Fairmount-managed investment vehicles. He disclaims beneficial ownership of the option and underlying shares, except for his pecuniary interest in those funds.
Is the Spyre Therapeutics (SYRE) Form 4 transaction an open-market purchase or sale?
No, the filing reports a stock option grant classified as a derivative award, not an open-market trade. The transaction code is “A,” indicating a grant or award acquisition rather than a purchase or sale on the open market.